Dateline City:
BOSTON
Company Provides Updates on Near-Term Opportunities and Immuno-Oncology Strategy
Announced Sale of Consumer Care Business to Bayer AG for $14.2 Billion; Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease
MK-3475 BLA Accepted for Priority Review by FDA; Company Announced Plans to File in EU in 2014
Provided Updates on Clinical Development Programs for Oncology, Hepatitis C and HIV
Confirmed Plans to File Odanacatib for the Treatment of Osteoporosis in Second Half of 2014
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today is hosting an Investor Briefing at the companys research facility
in Boston. The briefing is also available via webcast at www.merck.com
starting at 9:00 a.m. EDT.
Language:
English
Contact:
MerckMedia:Steve Cragle, 908-423-3461Ian McConnell 908-423-3046Investor:Joe Romanelli, 908-423-5185Carol Ferguson, 908-423-4465
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more